Authors: Wiseman, GA White, CA Stabin, M Dunn, WL Erwin, W Dahlbom, M Raubitschek, A Karvelis, K Schultheiss, T Witzig, TE Belanger, R Spies, S Silverman, DHS Berlfein, JR Ding, E Grillo-Lopezs, AJ

Citation: Ga. Wiseman et al., Phase I/II Y-90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma, EUR J NUCL, 27(7), 2000, pp. 766-777